A PHASE II CLINICAL TRIAL TO EVALUATE THE IMMUNOGENICITY AND REACTOGENICITY OF THE RECOMBINANT HIV-1 ENVELOPE VACCINES SF-2 RGP120 (CHO) [CHIRON VACCINES] IN MF59 ADJUVANT AND MN RGP120/HIV-1 [VAXGEN] IN ALUM ADJUVANT IN HEALTHY ADULTS: